ロード中...
Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens
BACKGROUND: Integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) offers persons living with HIV a potent new treatment option. Recently, local HIV clinicians noted weight gain in patients who switched from daily, fixed-dose efavirenz/tenofovir disoproxil fumarate/emtricitab...
保存先:
| 出版年: | Open Forum Infect Dis |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5631481/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.1094 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|